EP0904374A1 - Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation - Google Patents

Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation

Info

Publication number
EP0904374A1
EP0904374A1 EP97921834A EP97921834A EP0904374A1 EP 0904374 A1 EP0904374 A1 EP 0904374A1 EP 97921834 A EP97921834 A EP 97921834A EP 97921834 A EP97921834 A EP 97921834A EP 0904374 A1 EP0904374 A1 EP 0904374A1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
polypeptide
seq
interleukin
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97921834A
Other languages
German (de)
English (en)
Inventor
Reinhard Kurth
Michael Baier
Norbert Bannert
Albrecht Werner
Kurt Lang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Bundesrepublik Deutschland
Bundesministerium fuer Gesundheit
Original Assignee
Roche Diagnostics GmbH
Bundesrepublik Deutschland
Bundesministerium fuer Gesundheit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1996117203 external-priority patent/DE19617203A1/de
Priority claimed from DE19617202A external-priority patent/DE19617202A1/de
Application filed by Roche Diagnostics GmbH, Bundesrepublik Deutschland, Bundesministerium fuer Gesundheit filed Critical Roche Diagnostics GmbH
Publication of EP0904374A1 publication Critical patent/EP0904374A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5446—IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to polypeptides with LL-16 activity, processes for their preparation and their use.
  • the invention describes processed LL-16 with high activity
  • LL-16 Interleukin-16 is a lymphokine, which is also referred to as "lymphocyte chemoattracting factor” (LCF) or “immunodeficiency virus suppressing lymphokine” (ISL). Its properties are described in WO 94/28134 and in WO 96/31607 as well as by Cruikshank, WW, et al, Proc Natl Acad Sei USA 91 (1994) 5109-5113 and by Baier, M, et al, Nature 378 (1995) 563, which also describes the recombinant production of LL- 16. LL-16 is then a protein with a molecular mass of 13.385 D.
  • LCF lymphocyte chemoattracting factor
  • ISL immunodeficiency virus suppressing lymphokine
  • the object of the present invention is to improve the activity of LL-16 and to provide LL-16 forms which show low immunogenicity and are advantageously suitable for therapeutic use
  • the object of the invention is achieved by a nucleic acid with which the expression of a polypeptide with interleukin-16 activity in a prokaryotic or eukaryotic host cell can be achieved, said nucleic acid
  • nucleic acid preferably codes for a polypeptide with the amino acid sequence SEQ LD NO.2 or for a polypeptide with a sequence which is extended by an aspartic acid codon N-terminally compared to SEQ LD NO.2.
  • nucleic acid codes for a polypeptide with LL-16 activity, which is shortened by up to 8 amino acids at the C-terminus
  • Such a nucleic acid encodes a processed polypeptide with IL-16 activity, particularly preferably natural LL-16 from primates, such as human LL-16 or LL-16 from a monkey species or another mammal such as a mouse
  • FIG. 2 of WO 94/28134 does not describe the correctly processed LL-16.
  • the start codon "ATG" of the precursor form of the protein does not begin with nucleotide 783, but with nucleotide 54 or 174 if an A is inserted after nucleotide 156, a C after nucleotide 398 and a G after nucleotide 780.
  • the sequence also shows further differences from FIG. 2 of WO 94/28134. These are, for example, nucleotide exchanges (313 G in A, 717 C in A) In expression in eukaryotic cells, LL-16 is processed.
  • the sequence of LL-16 can differ to a certain extent from the protein sequences encoded by such DNA sequences. Such sequence variations can be amino acid exchanges, deletions or additions. However, the amino acid sequence of LL-16 is at least 75%, Particularly preferably at least 90% identical to the amino acid sequence of SEQ ID NO 2 Variants of parts of the amino and nucleic acid sequence SEQ LD NO 1 / SEQ LD NO 2 are for example in WO 96/31607 and the international patent applications PCT / EP96 / 05662 and PCT / EP96 / 05661 it is essential, however, that the polypeptides have a correct N-terminus. Preference is therefore given to proteins in which the first three to ten amino acids of the N-terminus are unchanged.
  • nucleic acids are understood to mean, for example, DNA, RNA and nucleic acid derivatives and analogs.
  • Preferred nucleic acid analogs are those compounds in which the sugar phosphate skeleton is replaced by other units, such as amino acids.
  • Such compounds are referred to as PNA and are described in WO 92/20702.
  • PNA-DNA bonds are stronger than DNA DNA bonds, the stringent conditions described below for PNA-DNA hybridization are not applicable. Suitable hybridization conditions are, however, described in WO 92/20703
  • LL-16 is to be understood as meaning a polypeptide with the activity of IL-16.
  • LL-16 preferably shows the stated effect in the test method described in WO 96/31607 or stimulates cell division according to WO 94 / 28134.
  • LL-16 binds to CD4 + lymphocytes and can suppress the replication of viruses such as HTV-1, HIV-2 and SIV.
  • the function of LL-16 is not limited by its presentation in the MHC complex
  • LL-16 exhibits one or more of the following properties
  • viruses preferably HIV-1, HIV-2 or
  • nucleic acids which hybridize under stringent conditions with nucleic acids of the sequence SEQ LD NO 1.
  • hybridize under stringent conditions means that two nucleic acid fragments under standardized hybridization Hybridize conditions with one another, as described, for example, in Sambrook et al, “Expression of cloned genes in E. coli” in Molecular Cloning A laboratory manual (1989), Cold Spring Harbor Laboratory Press, New York, USA.
  • Such conditions are, for example, hybridization in FIG. 6 , 0 x SSC at about 45 ° C, followed by a washing step at 2 x SSC at 50 ° C.
  • the salt concentration in the washing step can be, for example, between 2.0 x SSC at 50 ° C for low stringency and 0.2 x SSC at 50 ° C can be selected for high stringency.
  • the temperature of the wash step between room temperature, about 22 ° C, for narrow stringency and 65 ° C for high stringency can be varied
  • LL-16 is preferably produced recombinantly in prokaryotic or eukaryotic host cells. Such production processes are described, for example, in WO 94/28134 and WO 96/31607, which are also the subject matter of the disclosure of the present invention for this purpose. However, the forms of LL-16 according to the invention by recombinant production To be defined and reproducible, additional measures must be taken via the recombinant production methods familiar to those skilled in the art
  • Recombinant LL-16 can be produced according to the methods familiar to the person skilled in the art as heterologous expression or as homologous expression (after homologous recombination of the LL16 nucleic acid into the genome of the host organism).
  • a DNA is produced which is able to To produce protein which has the activity of LL-16.
  • the DNA is cloned into a vector which can be transferred into a host cell and can be replicated there.
  • a vector contains, in addition to the IL-16 sequence, regulatory elements which are necessary for the expression of the DNA sequence is required.
  • This vector which contains the LL-16 sequence and the regulatory elements, is transferred into a vector which is capable of expressing the DNA of LL-16 Amplification of the vector are suitable, cultivated and LL-16 won. Suitable measures ensure that the protein is an active tertiary str structure in which it shows LL-16 properties
  • the nucleic acid sequence of the protein can also be modified. Such modifications are, for example
  • the protein is preferably expressed in microorganisms, in particular in prokaryotes, and there in E. coli. Expression in prokaryotes leads to an unglycosylated polypeptide.
  • the expression vectors must contain a promoter which allows expression of the protein in the host organism.
  • promoters are known to the person skilled in the art and are, for example, lac promoter (Chang et al., Nature 198 (1977) 1056), trp promoter (Goeddel et al., Nuc. Acids Res. 8 (1980) 4057), ⁇ pj_ promoter ( Shimatake et al., Nature 292 (1981) 128) and T5 promoter (U.S. Patent No. 4,689,406).
  • Synthetic promoters such as, for example, the tac promoter (US Pat. No. 4,551,433) are also suitable.
  • Coupled promoter systems such as, for example, T7 RNA polymerase / promoter system (Studier et al., J. Mol. Biol. 189 (1986) 13) are also suitable.
  • Hybrid promoters consisting of a bacteriophage promoter and the operator region of the microorganism (EP-A 0267 851) are also suitable.
  • An effective ribosome binding site is required in addition to the promoter.
  • this ribosome binding site is referred to as the Shine-Dalgarno (SD) sequence (Sambrook et al., "Expression of cloned genes in E. coli" in Molecular Cloning.
  • SD Shine-Dalgarno
  • a DNA sequence which codes for the N-terminal part of an endogenous bacterial protein or another stable protein is usually attached to the 5'- End of the sequence coding for LL-16 fused. Examples include lacZ (Phillips and Silhavy, Nature 344 (1990) 882-884), trpE (Yansura, Meth. Enzymol. 185
  • the fusion proteins are preferably cleaved with enzymes (eg factor Xa) (Nagai et al “Nature 309 (1984) 810).
  • enzymes eg factor Xa
  • Further examples of cleavage sites are the IgA protease cleavage site (WO 91/11520, EP-A 0495 398), the ubiquitin cleavage site (Miller et al., Bio / Technology 7 (1989) 698) and the enterokinase cleavage site.
  • the proteins expressed in this way in bacteria are obtained in a conventional manner by digesting the bacteria and isolating the proteins
  • a fusion product which consists of the signal sequence which is suitable for the secretion of proteins in the host organisms used and the nucleic acid which encoded for the protein.
  • the protein is either secreted into the medium (in the case of gram-positive bacteria) or in the periplasmic space (in the case of gram-negative bacteria).
  • a cleavage site is expediently located, either during processing or in an additional step allows the protein to be split off.
  • signal sequences originate, for example, from ompA (Ghrayeb et al, EMBO J. 3 (1984) 2437), phoA (Oka et al., Proc Natl Acad. Sci. USA 82 (1985) 7212).
  • the vectors also contain terminators.
  • Terminators are DNA sequences that signal the end of a transcription process.They are usually characterized by two structural characteristics: a region that is rich in reversed G / C, which can form a double helix intramolecularly, and a number of U ( or T) residues Examples are the main terminator in the DNA of phage fd (Beck and Zink, Gene 16 (1981) 35-58) and rrnB (Brosius et al, J Mol. Biol 148 (1981) 107-127)
  • the expression vectors usually contain a selectable marker in order to select transformed cells.
  • selectable markers are, for example, the resistance genes for ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline (Davies et al., Ann Rev Microbiol 32 (1978) 469)
  • Selectable markers are the genes for essential substances of the biosynthesis of substances necessary for the cell, such as, for example, histidine, tryptophan and leucine
  • Suitable bacterial vectors are known.
  • vectors are described for the following bacteria: Bacillus subtilis (Palva et al., Proc Natl Acad Sei. USA 79 (1982) 5582), E. coli (Aman et al, Gene 40 (1985) 183, Studier et al, J. Mol Biol. 189 (1986) 113), Streptococcus cremoris (Powell et al, Appl Environ Microbiol 54 (1988) 655), Streptococcus lividans and Streptomyces lividans (U.S. Patent No. 4,747,056) Further genetic engineering processes for the production and expression of suitable vectors are described in J. Sambrook et al., Molecular Cloning a laboratory manual (1989), Cold Spring Harbor Laboratory Press, New York, NY.
  • yeast In addition to prokaryotic microorganisms, expression of recombinant LL-16 is also possible in eukaryotes (such as, for example, CHO cells, yeast or insect cells).
  • the yeast system or insect cells is preferred as the eukaryotic expression system.
  • Expression in yeast can be via three types of yeast vectors (integrating YIp (yeast integrating plasmids) - vectors, replicating YRp (yeast replicon plasmids) - vectors and episomal YEp (yeast episomal plasmids) - vectors). Kingsman et al, Tibtech 5 (1987) 53-57
  • the invention further relates to a prokaryotic or eukaryotic host cell which has been transformed or transfected with a nucleic acid which codes for an LL-16 polypeptide according to the invention in such a way that the host cell expresses the said polypeptide.
  • a host cell usually contains a biological one functional nucleic acid vector, preferably a DNA vector, a plasmid DNA, which contains this nucleic acid
  • a monomeric LL-16 polypeptide which cannot be split into further subunits is further preferred
  • nucleic acid and protein sequence of LL-16 described in WO 94/28134 do not correspond to the natural human sequences. It is merely a non-natural LL-16 analog. It is for therapeutic use however, it is preferred to use a protein which is either identical to the natural protein or differs only slightly from the natural protein and / or shows at least comparable activity and immunogenicity.
  • the sequence of the protein is described in SEQ LD NO.2 (optionally with an N-terminal extension by an aspartic acid residue and / or shortening at the C-terminus by up to 8 amino acids)
  • the nucleic acid sequence of LL-16 can receive deletions, mutations and additions within the scope of the invention.
  • the monomeric form of LL-16 can be multimerized. This allows the activity of LL-16 to be increased.
  • Such multimeric forms are preferably dimeric, tetrameric or octameric forms
  • the polypeptides of the invention can additionally contain a defined content of metal ions, the number of metal ions per subunit preferably being 0.5 to 2.
  • metal ions are suitable as metal ions in the sense of the invention. As has been shown, both alkaline earth metals and elements of the subgroups are suitable. Alkaline earth metals, cobalt, zinc, selenium, manganese, nickel, copper, iron, magnesium, calcium, molybdenum and silver are particularly suitable.
  • the ions can be one, two, three or four-valued. Divalent ions are particularly preferred.
  • the ions are preferably added as solutions of MgCl2, CaC ⁇ , MnCl2, BaCl2, LiC ⁇ , Sr (N03) 2, Na2Mo ⁇ 4, AgCi2.
  • the polypeptide according to the invention can be prepared by culturing a prokaryotic or eukaryotic host cell which has been transformed or transfected with a nucleic acid sequence according to claims 1 or 2 under suitable nutrient conditions and, if appropriate, isolating the desired polypeptide. If the preparation of the polypeptide is to take place in vivo as part of a gene therapy treatment, the polypeptide is of course not isolated from the cell.
  • the invention further relates to a pharmaceutical composition which contains a polypeptide according to the invention in an amount and / or specific activity sufficient for therapeutic use and, if appropriate, a pharmaceutically suitable diluent, adjuvant and / or carrier.
  • polypeptides according to the invention are particularly suitable for the treatment of pathological conditions which are caused by viral replication, in particular retroviral replication, and for immunomodulation. Such therapeutic applications are described in WO 96/31607. Diagnostic test methods are also described therein.
  • the polypeptides according to the invention can preferably be used for immunosuppression. This immunosuppression is preferably carried out by inhibiting the helper function of the THo and / or THi and / or TH2 cells.
  • the polypeptides according to the invention are accordingly of therapeutic value in all diseases in which an immunodisregulated O 97/41231 PC ⁇ YEP97 / 02216
  • ⁇ component in the pathogenesis is postulated, in particular hyperimmunity.
  • Diseases such as myocarditis, endocarditis and pericarditis can be considered as LL-16-treatable diseases in cardiology / angiology, in bronchitis, for example, bronchitis, asthma in hematology, autoimmune Europe and transplant rejection, and chronic gastritis in gastroenterology in endocrinology diabetes mellitus type I, in nephrology glomerulonephritis, diseases in the rheumatic range, diseases in ophthalmology, in neurology, such as multiple sclerosis, in dermatology eczema.
  • the polypeptides according to the invention can be used in autoimmune diseases, allergies and to avoid transplant rejections.
  • Another object of the invention is the use of the nucleic acids according to the invention in the context of gene therapy.
  • Suitable vector systems for this are, for example, retroviral or non-viral vector systems.
  • Another object of the invention is a polyclonal or monoclonal anti-LL-16 antibody or an immunoactive fragment thereof which SEQ ID NO is extended to the first 3-20 amino acids of SEQ ID NO.2 or an N-terminal by an aspartic acid residue: 2 binds, as well as methods for the production of such antibodies and their use for the determination of LL-16 and for the determination of viral infections in eukaryotic cells and in particular in mammalian cell material.
  • Virus-activated mammalian cells, in particular T cells can also be determined with LL-16.
  • Such antibodies are produced by immunization with a polypeptide according to the invention.
  • an antibody is carried out according to the methods familiar to the person skilled in the art, by immunization with an immunogen which extends the first 3-20 amino acids of SEQ ID NO: 2 or an N-terminally SEQ ID NO: Contains 2 as hapten.
  • the antibody can then be obtained from the immunized mammal in a conventional manner and, if appropriate, a monoclonal antibody can be produced.
  • RNA isolation Kit 5 ml denaturation solution (RNA isolation Kit, Stratagene) lysed. After the addition of 1 ml of Na acetate, 5 ml of phenol and 1 ml of chloroform / isoamyl alcohol (24 l), the lysate was kept on ice for 15 min. The aqueous phase was then washed with
  • the mixture for the cDNA synthesis contained 10 ⁇ g RNA, 0.2 ⁇ g Oiigo-dT, 13 mM DTT and 5 ⁇ l “bulk first strand reaction mix” (first-strand cDNA synthesis kit, Pharmacia) in an amount of 15 ⁇ l the mixture was incubated for 1 hour at 37 ° C and then stored at -20 ° C for later use
  • Amplification, cloning of LL-16 cDNA and production of an expression clone are carried out as described in WO 94/28134 or WO 96/31607, taking into account the changed sequences
  • Pre-cultures are prepared from stock cultures (plate smear or ampoules stored at -20 ° C), which are shaken and incubated at 37 ° C.
  • the inoculation volume into the next higher dimension is 1-10% by volume.
  • Ampicillin 50-100 mg / 1
  • the nutrients used are enzymatically digested protein and / or yeast extract as an N and C source, and glycerol and / or glucose as an additional C source.
  • the medium is buffered to pH 7 and metal salts are added to stabilize the fermentation process in physiologically acceptable concentrations.
  • the fermentation is carried out as a feed batch with a mixed yeast extract / C source dosage.
  • the fermentation temperature is 25-37 ° C.
  • the dissolved oxygen partial pressure (p ⁇ 2) is kept below about 20% via aeration rate, speed regulation and dosage speed.
  • the growth is determined by determining the optical density (OD) at 528 nm. Expression of the LL-16 is induced by means of IPTG. After a fermentation period of 10 to 20 hours, the biomass is harvested by centrifugation when the OD is at a standstill.
  • the biomass is taken up in 50 mM sodium phosphate, 5 mM EDTA, 100 mM sodium chloride, pH 7 and digested using a continuous high-pressure press at 1000 bar.
  • the suspension thus obtained is centrifuged again and the supernatant, which contains the dissolved LL-16, is processed further.
  • the column was then rinsed with 300 ml of 50 mM sodium phosphate, 0.5 M NaCl, pH 7.0 and the LL-16 fusion protein then with a gradient from 0 M to 300 mM imidazole, pH 7.0 in 50 mM Sodium phosphate, 0.1 M NaCl, pH 7.0 (2x 0.5 I gradient volume) eluted.
  • Fractions containing LL-16 were identified by SDS-PAGE, pooled and dialyzed against 20 mM sodium phosphate, pH 7.0.
  • 300 mg of the fusion protein thus obtained were dialyzed at 4 ° C. against 20 1 20 mM imidazole, pH 5.5 and then for 30 minutes to remove turbidity. centrifuged at 20,000 g. The supernatant from the centrifugation was then adjusted to pH 8.5 with NaOH, 0.3 mg of thrombin (Boehringer Mannheim GmbH) was added and the mixture was incubated at 37 ° C. for 4 hours. The gap mixture was then adjusted to pH 6.5 with HC1 and the conductivity to 1.7 mS by dilution with H2O.
  • LL-16 was eluted with a gradient of 0 to 0.3 M NaCl in 20 mM imidazole, pH 6.5. Fractions containing LL-16 were identified by SDS-PAGE and pooled. The identity of LL-16 was confirmed by mass analysis (molecular weight 13,566 + 3 D) and automated N-terminal sequence analysis.
  • an aminopeptidase for example ⁇ -aminoacylpeptide hydrolase
  • dipeptidyl peptidase for example catepsin CCATH
  • the LL-16 obtained in this way had a purity of more than 95% in SDS-PAGE under reducing conditions
  • a Vydac, Protein & Peptide Cl 8, 4x180 mm column was used for purity analysis using RP-HPLC. Elution is carried out by a linear gradient from 0% to 80% B (solvent B 90% acetonitrile in 0.1% TFA, solvent A 0 , 1% TFA in H2O) within 30 min with a flow rate of 1 ml / min. The detection was carried out at 220 nm
  • Amplification, cloning of LL-16 cDNA and production of an expression clone are carried out as described in WO 94/28134 or WO 96/31607, taking into account the changed sequences
  • An oligonucleotide of the sequence SEQ LD NO: 3 is used as the forward primer, which contains an EcoRI site, 6 His and an enterokinase cleavage site (D 4 K).
  • Cccgaattc tatg cat cac cac cac cac cac gatgacgacgacaaa-tctgcaqcctcaqcctctqc EcoRI H6 D4K
  • an oligonucleotide of the sequence SEQ ID NO: 6 is used as the forward primer, which also contains an EcoRI site, 6 His and an enterokinase cleavage site (D 4 K) cccgaattc tatg cat cac cac cac cac gatgacgacgacaaa-gactctqcaqcctcaqcctc EcoRI Hß D4K
  • Either oligonucleotide LL-16-Rj (SEQ ID NO: 4) is used as the reverse primer:
  • ILI6-R 1 qcq gat cca agc tta gga gtc tcc agc agc tgt g
  • oligonucleotide LL-16-R 2 SEQ LD NO: 5
  • ILI6-R 2 qcq qat cca agc tta ttc ctt gga ctg gag gct tttt tc
  • the two reverse primers contain BamHI and HindIII cloning sites
  • the PCR reaction, cloning and production of the expression clone are carried out according to standard conditions.
  • the column was then washed with equilibration buffer until the baseline (UV detection at 280 nm) was almost reached.
  • the column was then rinsed with 1 1 50 mM sodium phosphate, 0.5 M NaCl, pH 7.0 and with 1 1 50 mM sodium phosphate, 0.1 M NaCl, pH 7.0.
  • the fusion protein was eluted with a gradient of 0-300 mM imidazole, pH 7.0 in 50 mM sodium phosphate, 0.1 M NaCl, pH 7.0 (2 ⁇ 1.6 l).
  • Fractions containing IL 16 were identified by SDS-PAGE and pooled. This LL-16 pool was concentrated in the provario (Filtron, membrane Omega 5 K) to a concentration of 5 mg protein / ml and dialyzed against 50 mM Tris, pH 8 0
  • lymphocytes isolated from a "buffy coat" using Ficoll gradients are put into 500 ⁇ l PBS azide / 1 ⁇ 10 8 cells (phosphate buffered saline without Ca 2+ and Mg 2+ , 0.01% sodium azide, 5 mM EDTA , pH 7.2) resuspended After adding 20 ml CD8-Microbeads / lx 10? cells to be expected (mouse anti-human CD8 antibodies, conjugated with magnetic particles, Miltenyi Biotec GmbH) are incubated at 4 ° C. for 15 min.
  • the CD8 + cells to which the CD8 microbeads are coupled are retained in the column, the flow fraction accordingly contains all lymphocytes (approx. 80% CD4 + cells) with the exception of the CD8 + cells.
  • the column is removed from the holder and the CD8 + cell fraction eluted with PBS azide / 1% BSA.
  • the flow-through and the CD8 + cell fraction are centrifuged, resuspended in cell culture medium (RPMI 1640, 20% FCS, 2 mM glutamine, 180 U / ml LL-2), the cell number adjusted to 3 ⁇ 10 ⁇ cells / ml and the cells stimulated with PHA (9 mg / ml).
  • the quality of the lymphocyte subpopulation separation is checked by means of FACS.
  • the masses of the fragments are determined by mass spectrography and the size of the N-terminal fragment is thus determined.
  • a naturally processed IL-16 fragment was identified which begins with the N-terminus described in SEQ ID NO.1 / 2 or which is extended by an aspartic codon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'acide nucléique décrit permet d'exprimer un polypeptide à activité d'interleukine-16 dans une cellule hôte procaryote ou eucaryote. Cet acide nucléique code un polypeptide caractérisé par la séquence d'acides aminés SEQ ID NO:2 ou par la SEQ ID NO:2 prolongée, l'extrémité terminale N, d'un radical acide aspartique ou raccourcie, à l'extrémité terminale C, de 8 acides aminés au maximum. Cet acide nucléique est utile pour produire un polypeptide d'IL-16 actif.
EP97921834A 1996-04-30 1997-04-30 Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation Withdrawn EP0904374A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19617202 1996-04-30
DE19617203 1996-04-30
DE1996117203 DE19617203A1 (de) 1996-04-30 1996-04-30 Prozessierte Polypeptide mit IL-16-Aktivität, Verfahren zu ihrer Herstellung und Verwendung
DE19617202A DE19617202A1 (de) 1996-04-30 1996-04-30 Prozessierte Polypeptide mit IL-16-Aktivität, Verfahren zu ihrer Herstellung und Verwendung
PCT/EP1997/002216 WO1997041231A1 (fr) 1996-04-30 1997-04-30 Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation

Publications (1)

Publication Number Publication Date
EP0904374A1 true EP0904374A1 (fr) 1999-03-31

Family

ID=26025242

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97921834A Withdrawn EP0904374A1 (fr) 1996-04-30 1997-04-30 Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation

Country Status (11)

Country Link
US (1) US6506582B1 (fr)
EP (1) EP0904374A1 (fr)
JP (1) JP3251592B2 (fr)
KR (1) KR100308441B1 (fr)
CN (1) CN1217025A (fr)
AU (1) AU712122B2 (fr)
BR (1) BR9709205A (fr)
CA (1) CA2253259A1 (fr)
DE (1) DE19780377D2 (fr)
TR (1) TR199802168T2 (fr)
WO (1) WO1997041231A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2076777A4 (fr) * 2006-09-28 2009-12-30 Centocor Ortho Biotech Inc Méthode de détection de l'activité il-16 et modulation de l'activité il-16 en fonction de niveaux de stat-6 proxy phosphoryle
WO2008052165A2 (fr) * 2006-10-27 2008-05-02 Centocor Ortho Biotech Inc. Methodes de traitement des affections pulmonaires pathologiques et de la fibrose pulmonaire induite par la bleomycine
US20110217259A1 (en) * 2010-03-03 2011-09-08 Djordje Atanackovic IL-16 as a target for diagnosis and therapy of hematological malignancies and solid tumors
CN114984189B (zh) * 2022-05-27 2024-06-04 昆明理工大学 一种白细胞介素16蛋白的新用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
ES2320090T3 (es) * 1993-05-21 2009-05-19 Trustees Of Boston University Factor quimiotactico de linfocitos y usos del mismo.
DE19513152A1 (de) 1995-04-07 1996-10-10 Bundesrep Deutschland Verwendung eines "Immundefizienzvirus-supprimierenden Lymphokins (ISL)" zur Hemmung der Virusvermehrung, insbesondere von Retroviren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9741231A1 *

Also Published As

Publication number Publication date
DE19780377D2 (de) 1999-08-05
CA2253259A1 (fr) 1997-11-06
JPH11508453A (ja) 1999-07-27
WO1997041231A1 (fr) 1997-11-06
KR20000065005A (ko) 2000-11-06
TR199802168T2 (xx) 1999-02-22
AU712122B2 (en) 1999-10-28
US6506582B1 (en) 2003-01-14
AU2775297A (en) 1997-11-19
KR100308441B1 (ko) 2001-11-02
CN1217025A (zh) 1999-05-19
JP3251592B2 (ja) 2002-01-28
BR9709205A (pt) 2000-01-11

Similar Documents

Publication Publication Date Title
DE69233667T2 (de) Immunogene, nichtgiftige Mutanten des Choleratoxins und des Toxins-LT, ihre Herstellung und ihre Verwendung zur Herstellung von Impfstoffen
DE69827507T2 (de) Trimerisierendes modul
DE19605657B4 (de) Menschliches Proinsulinderivat, Kodierende DNA, DNA enthaltender Expressionsvektor, mit diesem transformierter Mikroorganismus und Verwendung dieses menschlichen Proinsulinderivats
DE69835756T2 (de) Hiv-1 tat und/oder nef enthaltende fusionsproteine
CA2494974A1 (fr) Substance de medicament a base d'il-7, composition, preparation et utilisations
DE3586972T2 (de) Gereinigtes interleukin-1.
AU627477B2 (en) Interleukin ii analogs
EP0870030A1 (fr) Polypeptide a activite d'il-16, son procede de fabrication et son utilisation
CA2234042A1 (fr) Nouveaux agonistes du recepteur du g-csf
EP0904374A1 (fr) Polypeptides traites a activite d'il-16, leur procede de preparation et leur utilisation
DE69324345T2 (de) Expression von osteogenem faktor op-1 in mit rekombinantem baculovirus infizierten spodoptera frugiperda-zellen
US6444202B1 (en) Processed polypeptides with IL-16 activity, processes for their production and their use
EP1307480B1 (fr) Trichosantine mutante
DE19617202A1 (de) Prozessierte Polypeptide mit IL-16-Aktivität, Verfahren zu ihrer Herstellung und Verwendung
JPH03297388A (ja) 新規なｔｎｆ変異体、その製造法及びそれを有効成分とする抗腫瘍剤
EP1051495A2 (fr) Lectines de gui recombinees
DE19649233A1 (de) Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung
DE19648715A1 (de) Prozessierte Polypeptide mit IL-16 Aktivität, Verfahren zu ihrer Herstellung und Verwendung
DE19617203A1 (de) Prozessierte Polypeptide mit IL-16-Aktivität, Verfahren zu ihrer Herstellung und Verwendung
EP0870029A1 (fr) Formes multimeres de il-16, leur procede de fabrication et leur utilisation
MXPA98008964A (en) Polypeptides processed with acativity il-16, processes for its production and its
DE19614099A1 (de) Genomische Nukleinsäuren, die für Polypeptide mit IL-16-Aktivität codieren, Verfahren zu ihrer Herstellung und Verwendung
CA2320624A1 (fr) Mutants d'il-16, leurs procedes de production et d'utilisation
JP2000510684A (ja) インターロイキン−３（ｉｌ−３）受容体アゴニスト
JP2002515729A (ja) 新規ｇ−ｃｓｆ受容体アゴニスト

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LANG, KURT

Inventor name: WERNER, ALBRECHT

Inventor name: BANNERT, NORBERT

Inventor name: BAIER, MICHAEL

Inventor name: KURTH, REINHARD

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LANG, KURT

Inventor name: WERNER, ALBRECHT

Inventor name: BANNERT, NORBERT

Inventor name: BAIER, MICHAEL

Inventor name: KURTH, REINHARD

17Q First examination report despatched

Effective date: 20030910

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040713